Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ALCAINE vs FLAGYL ER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Local anesthetic that stabilizes the neuronal membrane by inhibiting sodium ion influx, thereby blocking nerve impulse transmission.
Metronidazole, a nitroimidazole antibiotic, undergoes intracellular reduction by bacterial nitroreductases, forming cytotoxic compounds that damage DNA and inhibit nucleic acid synthesis, selectively targeting anaerobic bacteria and protozoa.
Ophthalmic anesthesia for procedures such as cataract extraction, tonometry, gonioscopy, and suture removal
Treatment of bacterial vaginosis (FDA-approved),Off-label: Clostridium difficile infection, anaerobic infections, trichomoniasis, amebiasis, giardiasis, rosacea, periodontal disease, Helicobacter pylori eradication
1 to 2 drops of 0.5% solution topically to the eye, repeated as needed for anesthesia.
750 mg orally once daily for 10 days for bacterial vaginosis.
Terminal elimination half-life: 0.4–1.2 minutes (rapid enzymatic hydrolysis by plasma esterases); clinical significance: ultra-short duration limits systemic toxicity.
Terminal elimination half-life: 6-8 hours (increased to 10-12 hours with hepatic impairment; unchanged in renal impairment).
Hydrolyzed by plasma esterases.
Hepatic metabolism via side-chain oxidation and glucuronidation; metabolites are 5-nitroimidazoles and hydroxy metabolites; CYP450 enzymes (CYP2A6, CYP3A4, CYP2B6) partially involved.
Renal excretion of parent drug and metabolites: <5% unchanged.
Renal: 60-80% (metabolites and unchanged drug). Fecal: 6-15%. Minimal biliary.
Minimal; <5% bound to plasma proteins.
<20% (albumin).
Not clinically meaningful due to rapid hydrolysis; Vd estimated <0.5 L/kg (low, consistent with high water solubility and rapid clearance).
0.5-0.8 L/kg; indicates extensive tissue distribution including CNS.
Ophthalmic topical: negligible systemic absorption (minimal bioavailability); not applicable systemically.
Oral: 80-95% (extended-release formulation).
No dose adjustment required; negligible systemic absorption.
No adjustment necessary for GFR >10 m L/min; for GFR <10 m L/min, consider using immediate-release metronidazole instead of FLAGYL ER due to lack of data in severe renal impairment.
No dose adjustment required; negligible systemic absorption.
Child-Pugh Class A/B: no adjustment necessary. Child-Pugh Class C: reduce dose to 375 mg orally once daily (50% of usual dose).
1 drop of 0.5% solution topically to the eye, repeated as needed; maximum 1 drop per dose in infants and young children to avoid systemic effects.
Safety and efficacy not established for FLAGYL ER in pediatric patients. Use immediate-release metronidazole for pediatric dosing.
No specific adjustment; use lowest effective dose due to potential increased corneal sensitivity and delayed healing.
No specific dose adjustment recommended based on age alone; use caution due to potential for decreased renal function and monitor for adverse effects.
Not for injection or prolonged use; corneal toxicity with repeated or prolonged use.
Carcinogenicity: Metronidazole has been shown to be carcinogenic in mice and rats. Avoid chronic use. Reserved for anaerobic and protozoal infections.
Prolonged use may cause corneal epithelial damage and delay wound healing. Avoid contamination of the dropper tip.
Peripheral neuropathy (risk with prolonged use), CNS effects (seizures, encephalopathy), disulfiram-like reaction with alcohol, sodium overload (each tablet contains 84 mg sodium), hepatic impairment may increase risk of toxicity, renal impairment (dose adjustment not typically required but monitor), superinfection including C. difficile diarrhea.
Hypersensitivity to any component of the formulation.
Hypersensitivity to metronidazole or other nitroimidazoles; concurrent use of disulfiram (psychotic reactions); caution in pregnancy (first trimester only if clearly needed; crosses placenta); breastfeeding (use caution due to potential carcinogenicity).
None known.
Avoid alcohol and any products containing alcohol (e.g., mouthwash, cough syrups, cooking wine) during therapy and for 48 hours after last dose. No specific food restrictions otherwise.
Proparacaine (ALCAINE) is an ophthalmic local anesthetic. Systemic absorption is negligible after topical ocular administration. No adequate well-controlled studies in pregnant women. Animal studies showed no teratogenic effects at doses up to 0.5 mg/kg (SC). Potential fetal risk unlikely to exceed background risk. No known trimester-specific risks.
Trimester 1: Crosses placenta; contraindicated in first trimester due to risk of carcinogenicity in animal studies and potential teratogenicity; use only for life-threatening infections. Trimester 2 and 3: Use with caution; associated with increased risk of cleft lip/palate in some studies; avoid if possible.
Proparacaine is excreted into breast milk in unknown amounts, but due to minimal systemic absorption, the expected dose to infant is negligible. Manufacturer advises caution. No M/P ratio available.
Excreted in breast milk; M/P ratio ~0.9; American Academy of Pediatrics considers compatible with breastfeeding, but advise caution; monitor infant for diarrhea or oral thrush.
No dosing adjustment required for topical ophthalmic use due to negligible systemic absorption and lack of pharmacokinetic alterations in pregnancy.
No specific dose adjustments recommended based on pregnancy pharmacokinetics; however, due to increased GFR in pregnancy, consider monitoring therapeutic levels for severe infections.
ALCAINE (proparacaine) is a topical ophthalmic anesthetic. Onset within 20 seconds, duration ~15 minutes. Do not dispense for home use due to risk of corneal toxicity with prolonged use. Use a sterile, single-dose vial to prevent contamination. Monitor for stinging or burning on instillation. Avoid in patients with sulfite allergy (contains sodium bisulfite).
FLAGYL ER (metronidazole extended-release) is indicated for bacterial vaginosis. Avoid alcohol during therapy and for 48 hours after completion due to disulfiram-like reaction. Monitor for peripheral neuropathy; discontinue if signs occur. Use with caution in hepatic impairment; dose adjustment may be needed. May cause metallic taste.
Temporary stinging or burning may occur upon application.,Do not touch the dropper tip to any surface to avoid contamination.,Do not use for more than instructed; prolonged use can damage the cornea.,Remove contact lenses before use and wait at least 15 minutes before reinserting.,Notify your doctor if you have a sulfite allergy.
Take this medication exactly as prescribed; do not crush or chew the extended-release tablets.,Avoid all alcohol and alcohol-containing products during treatment and for 48 hours after the last dose to prevent severe nausea, vomiting, and flushing.,Complete the full course even if symptoms improve to ensure infection is fully treated.,Report any numbness, tingling, or pain in hands or feet to your doctor immediately.,Inform your healthcare provider if you have liver disease, a history of blood disorders, or are pregnant or breastfeeding.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ALCAINE vs FLAGYL ER, answered by our medical review team.
ALCAINE is a Local Anesthetic that works by Local anesthetic that stabilizes the neuronal membrane by inhibiting sodium ion influx, thereby blocking nerve impulse transmission.. FLAGYL ER is a Nitroimidazole Antibiotic that works by Metronidazole, a nitroimidazole antibiotic, undergoes intracellular reduction by bacterial nitroreductases, forming cytotoxic compounds that damage DNA and inhibit nucleic acid synthesis, selectively targeting anaerobic bacteria and protozoa.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ALCAINE and FLAGYL ER depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ALCAINE is: 1 to 2 drops of 0.5% solution topically to the eye, repeated as needed for anesthesia.. The standard adult dose of FLAGYL ER is: 750 mg orally once daily for 10 days for bacterial vaginosis.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ALCAINE and FLAGYL ER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ALCAINE is classified as Category C. Proparacaine (ALCAINE) is an ophthalmic local anesthetic. Systemic absorption is negligible after topical ocular administration. No adequate well-controlled studies in pregnant wom. FLAGYL ER is classified as Category C. Trimester 1: Crosses placenta; contraindicated in first trimester due to risk of carcinogenicity in animal studies and potential teratogenicity; use only for life-threatening infec. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.